Abivax SA Cash Flow Conversion Efficiency

Latest as of March 2026: -0.118x

Abivax SA cash flow conversion efficiency. Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-50.52 Million ≈ $-59.06 Million USD) by net assets (€429.59 Million ≈ $502.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Abivax SA (2013–2025)

Cash flow conversion efficiency of Abivax SA from 2013 to 2025. This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABVX live share price for real-time trading data and today's change.

Abivax SA Cash Flow Conversion Ratio Explained

Abivax SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Abivax SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency. Also see Abivax SA market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Shanghai Commercial & Savings Bank Ltd TW:5876	0.029x
Sharetronic Data Technology Co Ltd SHE:300857	0.047x
Shenzhen Kinwong Electronic Co Ltd SHG:603228	0.030x
SRF Limited NSE:SRF	0.080x
Spyre Therapeutics Inc. NASDAQ:SYRE	-0.063x
BOK Financial Corporation NASDAQ:BOKF	0.015x
Jackson Financial Inc NYSE:JXN	0.106x
Jinduicheng Molybdenum Co Ltd SHG:601958	0.070x

Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2025. Review Abivax SA leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€455.20 Million ≈ $532.18 Million	€-162.09 Million ≈ $-189.50 Million	-0.356x	+90.62%
2024-12-31	€40.58 Million ≈ $47.45 Million	€-154.07 Million ≈ $-180.13 Million	-3.796x	-666.11%
2023-12-31	€196.01 Million ≈ $229.16 Million	€-97.13 Million ≈ $-113.56 Million	-0.496x	+98.58%
2022-12-31	€1.88 Million ≈ $2.20 Million	€-65.58 Million ≈ $-76.67 Million	-34.845x	-2096.03%
2021-12-31	€28.77 Million ≈ $33.64 Million	€-45.66 Million ≈ $-53.38 Million	-1.587x	+75.14%
2020-12-31	€4.67 Million ≈ $5.46 Million	€-29.82 Million ≈ $-34.87 Million	-6.382x	-173.67%
2019-12-31	€11.78 Million ≈ $13.77 Million	€-27.47 Million ≈ $-32.12 Million	-2.332x	-453.39%
2018-12-31	€34.65 Million ≈ $40.51 Million	€-14.60 Million ≈ $-17.07 Million	-0.421x	-140.30%
2017-12-31	€48.18 Million ≈ $56.33 Million	€-8.45 Million ≈ $-9.88 Million	-0.175x	+36.28%
2016-12-31	€56.72 Million ≈ $66.31 Million	€-15.61 Million ≈ $-18.25 Million	-0.275x	-32.46%
2015-12-31	€71.74 Million ≈ $83.87 Million	€-14.90 Million ≈ $-17.42 Million	-0.208x	-113.32%
2014-12-31	€33.94 Million ≈ $39.67 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	-0.25%
2013-12-31	€34.02 Million ≈ $39.77 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$7.87 Billion

€6.73 Billion EUR

Market Cap Rank

#2563 Global

#53 in France

Share Price

€77.15

Change (1 day)

-0.64%

52-Week Range

€63.10 - €135.00

All Time High

€135.00